PK–PD Interaction Study of Angiotensin II Antagonist, Losartan, with Selective Estrogen Receptor Modulator, Centchroman

Abstract

Aim:The effect on pharmacokinetics and postcoital contraceptive efficacy of centchroman was investigated after concomitant administration of losartan. Materials & methods: An LC-MS/MS method was employed for quantification of centchroman in blood of female rats treated with centchroman (1.5 mg/kg) only and centchroman plus losartan (5 mg/kg, once daily up to day 7). The effect of losartan on the postcoital contraceptive activity of centchroman was evaluated in sperm-positive female rats. Results:The area under the curve and mean residence time values were decreased in losartan concomitant group, however, sperm-positive female rats did not exhibit any implantations in either centchroman only or losartan co-administered group of female rats. Conclusion: The study evidenced no pharmacological interaction of losartan with centchroman.

Welcome to the International Journal of Pharmacokinetics

“…He proposes the abolishment of 'fold' from our lexicon to reduce confusion and misinterpretation when reading scientific literature. Sharma et al [4] describe their study on the pharmacokinetic and pharmacodynamic interaction between the selective estrogen receptor modulator oral contraceptive centchroman and losartan, an angiotensin II receptor antagonist used for long-term therapy of hypertension. In their original research article, Tod et al [5] compare different techniques for quantitatively predicting the magnitude of drug-drug interactions.…”